Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

David Thompson

Trial Manager - Oncology Clinical Trial Office (OCTO)

I started at OCTO as a Clinical Trial Support Officer in 2015, with no previous experience in clinical trials; however, the position provided me with a great opportunity to start an exciting new career and develop my career skills within a motivating department. OCTO provided regular training sessions and support which enabled me to learn about all aspects of clinical trials, and after 3 years I was promoted to a Clinical Trial Administrator, and to Trial Manager in January 2020.

I currently work on:

IMP-MEL: A phase 1 first-in-human dose finding/randomised phase 2 study of IMM60 and pembrolizumab in advanced melanoma and NSCLC

CEeDD: A First-in-Human Clinical Investigation of Cavitation-Enhanced Drug Delivery to Solid Tumours by co-Administration of Sonosensitive Particles and Application of Extracorporeal Ultrasound in Patients with Colorectal Metastases to the Liver

I have previously worked on:

AspECT: A Phase III, randomised study of aspirin and esomeprazole chemoprevention in Barrett's metaplasia.

CAMELLIA: A Phase I dose escalation trial of the Humanized Anti-CD47 Monoclonal Antibody Hu5F9-G4 in Haematological Malignancies

NuTIDE:301: A two-part, Phase 1 open-label dose escalation and expansion study to assess safety, pharmacokinetics and clinical activity of NUC-3373, a nucleotide analogue, in participants with advanced solid tumours.